HCV drug marketplace poised for growth – investors taking note
About 3 percent of the world’s population has been infected with the hepatitis C virus (HCV) and more than 170 million chronic carriers are at risk of developing serious related diseases such as liver cirrhosis and liver cancer, the World Health Organization estimates. It is not surprising then that the global market for new HCV medicines is poised for dramatic growth.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter